Allarity Therapeutics, Inc.

ALLR Healthcare Biotechnology

Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.

0.90 0.07 +8.43%
Market cap
$13.2M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
n/a
Altman Z
−10.51
Beneish M
n/a
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Gross Profit
— 0.02 — —

+8 more TTM periods

Operating Income
(11.11) (12.58) (12.92) (17.00)
EBT
(12.33) (11.25) (11.23) (15.31)
Income after Tax
(12.33) (11.25) (11.23) (15.31)
Net Income Common
(12.33) (11.25) (11.23) (15.31)
EPS (Diluted)
(0.78) (0.72) (0.80) 652.60
Shares (Diluted, Weighted)
15.25 15.16 13.95 10.76
Gross Margin
— 0.00% — —
EBIT Margin
0.00% 0.00% 0.00% 0.00%
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Margin
0.00% 0.00% 0.00% 0.00%
EBITDA
(11.14) (12.63) (12.94) (17.02)
EBIT
(10.79) (12.26) (12.60) (17.00)

Show all line items

In millions of $ except per-share values · columns are period end dates